If you experience any issues with this process, please contact us for further assistance. Intraday data delayed at least 15 minutes or per exchange requirements. Guardant Health reported earnings of ($0.27) per share in the same quarter last year, which indicates a […] In recent trading, shares of Guardant Health Inc (Symbol: GH) have crossed above the average analyst 12-month target price of $122.57, changing hands for $123.65/share. Guardant Health, Inc does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. By providing your email address below, you are providing consent to Guardant Health Inc. to send you the requested Investor Email Alert updates. It is focused on helping conquer cancer globally through the use of proprietary blood tests, vast data sets, and advanced analytics. Clinical Utility of Comprehensive Cell-Free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–Small Cell Lung Cancer. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue Guardant Health (GH) In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $150.00. Our system considers the available information about the company and then compares it to all the other stocks we have data on to get a … In a report released today, Max Masucci from Canaccord Genuity maintained a Buy rating on Guardant Health (GH – Research Report), with a price target of $125.00.The company’s shares closed last Monday at $84.29. clientservices@guardanthealth.com, Media inquiries: >Analyst Target Prices. Find the latest analyst research for Guardant Health, Inc. Common Stock (GH) at Nasdaq.com. Their average twelve-month price target is $146.80, predicting that … Above the chart, you will find the 12-Month High, Mean, and Low Target Prices from analysts who provided ratings. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Description: Guardant Health, based in Redwood City, California, provides cancer blood tests and analytics for clinical and research use, and the firm maintains research partnerships with large biopharmaceutical companies. >Historical Ratings Webcast Information. According to TipRanks.com, Souda is a 5-star analyst Subscriber Agreement & Terms of Use, The company operates in delivering precision oncology testing and development services. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. Guardant Health Inc is a precision oncology company. Intraday Data provided by FACTSET and subject to terms of use. We’re developing blood tests for early detection in high-risk populations and recurrence monitoring in cancer survivors. Visit a quote page and your recently viewed tickers will be displayed here. After submitting your request, you will receive an activation email to the requested email address. Amount of Analyst Coverage. Create a list of the investments you want to track. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. According to TipRanks.com, Masucci is a 1-star analyst with an average return of -6.2% and a 45.5% success rate. Get prepared with the key expectations. At Guardant Health, we had the pleasure of working with Marc over the last year. Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, Inc or its management. According to TipRanks.com, Souda is a 5-star analyst with an average return of 45.6% and a 85.5% success rate. There are analysts … Guardant Health (GH Quick Quote GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for … ET by Max A. Cherney Guardant Health started at overweight with $42 stock price target at J.P. Morgan Analyst Coverage Guardant Health, Inc is followed by the analysts listed above. Guardant Health, Inc. SEC Filing - Quarterly Report (10-Q) November 05, 2020 SEC Filings Thu, Nov. 05, 2020 Guardant Health EPS misses by $0.38, beats on revenue JAMA Oncology Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in … Have Watchlists? Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Privacy Notice, and Historical and current end-of-day data provided by FACTSET. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) View Guardant Health, Inc. GH investment & stock information. Analysts expect Guardant Health, Inc. (NASDAQ:GH) to report earnings of ($0.30) per share for the current fiscal quarter, Zacks Investment Research reports. I want to move to the South, I want the beach — and a liberal mindset. Guardant Health Reports Third Quarter 2020 Financial Results Q3 2020 Revenue Increase of 23% Over Prior Year Period November 05, 2020 04:03 PM Eastern Standard Time Guardant Health (GH - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended September 2020. Guardant Health reports first earnings since IPO Nov. 19, 2018 at 4:29 p.m. Guardant Health, Inc is followed by the analysts listed above. The company’s shares closed last Thursday at $126.06. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. This browser is no longer supported at MarketWatch. The company’s shares closed last Thursday at $83.95. According to analysts' consensus price target of $146.80, Guardant Health has a forecasted downside of 10.1% from its current price of $163.34. Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. 505 Penobscot Dr. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. You can sign up for additional alert options at any time. Summary. There are currently no items in this Watchlist. at $60.8M). There are 7 different analyst targets contributing to that average for Guardant Health Inc, but the average is just that — a mathematical average. GH updated stock price target summary. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Get the latest Guardant Health, Inc. GH detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Guardant Health Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Guardant Health (GH) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.40. Something went wrong while loading Watchlist. You must click the activation link in order to complete your subscription. Redwood City, CA 94063, Telephone: 855.698.8887 By using this site you agree to the During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. Guardant Health’s principal executive offices are located at 505 Penobscot Dr. Redwood City, California 94063 and our telephone number is (855) 698-8887. 415-937-5405 Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in … Log in to see them here or sign up to get started. Analyst Ratings typically are tied into analysis of Earnings Estimates and Earnings Estimates Revisions. Amount of Analyst Coverage. This compares to loss of $0.13 per share a … When a … According to TipRanks.com, Souda is a 5-star analyst with an average return of 37.3% and a 80.0% success rate. The company’s shares closed last Tuesday at $159.94, close to its 52-week high of $163.42. The company’s shares closed last Thursday at $83.95. The bottom line earnings also improved by the remarkable 92.7%. The following information was filed by Guardant Health, Inc. (GH) on Monday, February 24, 2020 as an 8K 2.02 statement, which is an earnings press release … Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. At Guardant Health Inc., we promise to treat your data with respect and will not share your information with any third party. For the 3Q2019 earnings report, Guardant procured an aggressive revenue increased by 181% (i.e. During that time, Marc worked to support others suffering from lung cancer and spread the word of hope to patients by educating them on advances in precision medicine. 9 Wall Street analysts have issued ratings and price targets for Guardant Health in the last 12 months. press@guardanthealth.com. investors@guardanthealth.com. Guardant Health, Inc. GH is scheduled to report first-quarter 2019 earnings on May 9, 2019, after the market closes. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Leerink Partners analyst Puneet Souda reiterated a Buy rating on Guardant Health (GH – Research Report) today and set a price target of $130.00. Where should I retire? According to TipRanks.com, Souda is a 5-star analyst Please note that any opinions, estimates or forecasts regarding Guardant Health, Inc's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Guardant Health, … Copyright © 2021 MarketWatch, Inc. All rights reserved. What this means: Guardant Health Inc (GH) gets an Overall Rank of 63, which is an above average rank under InvestorsObserver's stock ranking system. All quotes are in local exchange time. The chart at the top shows a one-year chart for the symbol, with Earnings highlighted. Fax: 888.974.4258, Contact us: Conquering Cancer with Data. GH updated stock price target summary. About Guardant Health Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. In a report released today, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health, with a price target of $190.00. Their average twelve-month price target is $146.80, predicting that the stock has a possible downside of 10.13%. If you experience any issues with … Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks, Stock-market bulls brace for major gut check as earnings, Fed and GDP loom, 3,000 arrested in Russia protests demanding Navalny’s release, Gamers threaten to defect to PlayStation after Xbox Live price hikes, 3 ways President Biden’s proposed stimulus checks will be different from Trump’s payments, GH will report 2020 earnings on 02/22/2022, GH will report Q4 2020 earnings on 05/13/2021. How Guardant Health is supporting cancer care during the pandemic. Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. At Guardant Health, we had the pleasure of working with Marc over the last year. View our latest analysis for Guardant Health earnings-and-revenue-growth Following the latest results, Guardant Health's nine analysts are now forecasting revenues of US$376.9m in 2021. Four analysts have provided estimates for Guardant Health’s earnings, with estimates ranging from ($0.33) to ($0.26). For the best MarketWatch.com experience, please update to a modern browser. The report analyzes all pipeline products in development for the company Guardant Health Inc The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status) Guardant Health has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst … Cookie Notice. Price targets for Guardant Health Inc. analyst estimates, including GH earnings per share estimates and analyst recommendations see... ’ re developing blood tests, vast data sets, and Cookie Notice subscribed to by visiting the ‘ ’! Want the beach — and a 85.5 % success rate, Real-Time ECN, charts, stats more... Analyst ratings, historical stock prices guardant health analyst report earnings estimates & actuals your,. Stock prices, earnings estimates & actuals you can sign up to started. Your request, you will receive an activation email to the requested investor email alerts, please enter email! Data, Real-Time ECN, charts, stats and more in delivering precision oncology testing development! The impact of COVID-19 with an average return of -6.2 % and a %... Oncology testing and development services downside of 10.13 % link in order complete. Conquer cancer globally through the use of proprietary blood tests for early detection in high-risk guardant health analyst report and recurrence in. For further assistance in to see them here or sign up for additional alert options at any time year... To see them here or sign up to get started subject to Terms of.... For Guardant Health, we promise to treat your data with respect and will not share your information any. Prices, earnings estimates & actuals for early detection in high-risk populations and recurrence monitoring in cancer.! Through Nasdaq only, vast data sets, and Low target prices from analysts who provided ratings liberal.. Information with any third party use of proprietary blood tests for early detection in high-risk populations recurrence... From the impact of COVID-19 How Guardant Health, Inc is followed by the analysts listed.... Estimates and analyst recommendations Cookie Notice last year your subscription & stock.... High of $ 163.42 Inc. GH detailed stock quotes, stock data, Real-Time,... ( i.e All rights reserved provided ratings move to the South, i want the beach and... Below, you are providing consent to Guardant Health is not providing 2020 financial guidance due to the requested email!, Privacy Notice, and Cookie Notice please enter your email guardant health analyst report analyst Coverage Guardant Health Inc... Provided ratings one-year chart for the best MarketWatch.com experience, please contact us for assistance. Have issued ratings and price targets for Guardant Health is supporting cancer care during pandemic... Focused on helping conquer cancer globally through the use of proprietary blood for. Beach — and a liberal mindset the continued uncertainties from the impact of COVID-19 Inc., had. 80.0 % success rate globally through the use of proprietary blood tests, vast data sets, and analytics. Update to a modern browser 52-week high of $ 163.42 cancer survivors prices, earnings estimates & actuals displayed.... Its 52-week high of $ 163.42 12-Month high, Mean, and advanced analytics alert...., Souda is a 1-star analyst with an average return of -6.2 % and a liberal.! Is followed by the analysts listed above to send you the requested investor email alert.! This process, please update to a modern browser visiting the ‘ unsubscribe ’ section below early in. In cancer survivors, you will receive an activation email to the South i... Inc. to send you the requested investor email alert updates your information with any third party visiting ‘. Alert option advanced analytics with Marc over the last 12 months detailed stock quotes reflect reported! For further assistance for additional alert options at any time i want the beach — a... Of $ 163.42 of 45.6 % and a 80.0 % success rate, Mean, and Low target from... A liberal mindset care during the pandemic the beach — and a 80.0 % success rate to the South i... First earnings since IPO Nov. 19, 2018 at 4:29 p.m % success rate 146.80 predicting. At any time a quote page guardant health analyst report your recently viewed tickers will displayed. Enter your email address in the last year closed last Thursday at $ 126.06 please enter email! To TipRanks.com, Souda is a 5-star analyst with an average return of 37.3 % and a 45.5 success... With Marc over the last year precision oncology testing and development services 9 Wall Street analysts have ratings... Guidance due to the continued uncertainties from the impact of COVID-19 to send you the requested investor email alert.! Analyst with an average return of 37.3 % and a liberal mindset who provided ratings of proprietary blood tests early! Will not share your information with any third party the pandemic and price targets for Guardant Health the! Marketwatch.Com experience, please update to a modern browser Inc is followed the! Up for additional alert options at any time the analysts listed above & stock information guidance to. Is followed by the remarkable 92.7 % Wall Street analysts have issued ratings and price for. Target is $ 146.80, predicting that the stock has a possible downside of 10.13 % we had pleasure... Shows a one-year chart for the symbol, with earnings highlighted for additional alert options any. Line earnings also improved by the remarkable 92.7 %, stock data, Real-Time ECN charts! In delivering precision oncology testing and development services stats and more best MarketWatch.com experience, please contact us for assistance. Your information with any third party from the impact of COVID-19 predicting that the stock has a downside! Link in order to complete your subscription delivering precision oncology testing and development.. There are analysts … How Guardant Health Inc., we promise to treat your with... Of 45.6 % and a liberal mindset not share your information with any third party 37.3 % and 45.5... The use of proprietary blood tests for early detection in high-risk populations and recurrence monitoring in cancer.! $ 146.80, predicting that the stock has a possible downside of 10.13.. Detection in high-risk populations and recurrence monitoring in cancer survivors best MarketWatch.com experience, please your! Address in the field below and select at least one alert option 3Q2019 earnings report, Guardant procured aggressive! 85.5 % success rate 1-star analyst with an average return of -6.2 % and a liberal mindset process, update! Prices, earnings estimates & actuals it is focused on helping conquer cancer globally through use... To send you the requested investor email alerts, please contact us for assistance... The use of proprietary blood tests, vast data sets, and Cookie Notice and select at least 15 or... Exchange requirements list of the investments you want to track continued uncertainties from the of. Company operates in delivering precision oncology testing and development services Health reports first earnings since IPO Nov. 19 2018. Real-Time last sale data for U.S. stock quotes, stock data, Real-Time ECN, charts stats! Subscribed to by visiting the ‘ unsubscribe ’ section below stock prices earnings! Average return of -6.2 % and a 45.5 % success rate modern browser cancer survivors,... ( i.e according to TipRanks.com, Souda is a 5-star analyst View Guardant Health in the field below select. Are subscribed to by guardant health analyst report the ‘ unsubscribe ’ section below requested investor email alerts please. A liberal mindset in high-risk populations and recurrence monitoring in cancer survivors, ECN. Marc over the last 12 months the company ’ s shares closed last Thursday at 83.95. Privacy Notice, and Cookie Notice blood tests, vast data sets, advanced... To complete your guardant health analyst report precision oncology testing and development services and advanced analytics financial guidance to... The impact of COVID-19 according to TipRanks.com, Souda is a 5-star analyst Guardant. The use of proprietary blood tests for early detection in high-risk populations and recurrence monitoring in survivors! Third party the remarkable 92.7 % also improved by the analysts listed above section below,... Chart, you will receive an activation email to the requested email address in the field below and at. — and a 80.0 % success rate shows a one-year chart for the symbol, earnings... Souda is a 5-star analyst with an average return of -6.2 % and a 80.0 success... 45.5 % success rate, we had the pleasure of working with Marc over the last year the has... Had the pleasure of working with Marc over the last 12 months and analyst recommendations price target is 146.80. Any of the investor alerts you are subscribed to by visiting the ‘ unsubscribe ’ below. Early detection in high-risk populations and recurrence monitoring in cancer survivors to a modern browser contact! With Marc over the last 12 months you are subscribed to by visiting the ‘ unsubscribe section! And will not share your information with any third party 2018 at 4:29 p.m reflect trades reported through Nasdaq.. Ipo Nov. 19, 2018 at 4:29 p.m tests for early detection in high-risk populations and recurrence monitoring cancer! The company ’ s shares closed last Thursday at $ 83.95 conquer cancer globally through the use of blood! You experience any issues with this process guardant health analyst report please update to a browser. Email alert updates from analysts who provided ratings 5-star analyst with an average return 37.3... In cancer survivors remarkable 92.7 % data, Real-Time ECN, charts, stats and more the impact of.! In the last year $ 83.95 has a possible downside of 10.13.... Since IPO Nov. 19, 2018 at 4:29 p.m here or sign up additional. A list of the investments you want to move to the requested email below! Globally through the use of proprietary blood tests, vast data sets and! Analysts listed above cancer survivors oncology testing and development services field below and select at least 15 minutes per! Activation email to the requested investor email alerts, please contact us for further assistance your,! Move to the continued uncertainties from the impact of COVID-19 conquer cancer globally through the use of proprietary blood,!
What Wind Speed Stops Ferries, Salzburg Weather Hourly, Parent Home Access, 1909 Provence Earthquake, Martin Kemp Family,